GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (NSE:AUROPHARMA) » Definitions » Cyclically Adjusted PS Ratio

Aurobindo Pharma (NSE:AUROPHARMA) Cyclically Adjusted PS Ratio : 2.87 (As of May. 31, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aurobindo Pharma Cyclically Adjusted PS Ratio?

As of today (2024-05-31), Aurobindo Pharma's current share price is ₹1218.90. Aurobindo Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was ₹425.18. Aurobindo Pharma's Cyclically Adjusted PS Ratio for today is 2.87.

The historical rank and industry rank for Aurobindo Pharma's Cyclically Adjusted PS Ratio or its related term are showing as below:

NSE:AUROPHARMA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.08   Med: 2.16   Max: 3.35
Current: 2.87

During the past years, Aurobindo Pharma's highest Cyclically Adjusted PS Ratio was 3.35. The lowest was 1.08. And the median was 2.16.

NSE:AUROPHARMA's Cyclically Adjusted PS Ratio is ranked worse than
61.91% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.09 vs NSE:AUROPHARMA: 2.87

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Aurobindo Pharma's adjusted revenue per share data for the three months ended in Mar. 2024 was ₹128.364. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹425.18 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Aurobindo Pharma Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Aurobindo Pharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma Cyclically Adjusted PS Ratio Chart

Aurobindo Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.50 2.89 1.98 1.35 2.56

Aurobindo Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 1.83 2.24 2.59 2.56

Competitive Comparison of Aurobindo Pharma's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurobindo Pharma's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's Cyclically Adjusted PS Ratio falls into.



Aurobindo Pharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Aurobindo Pharma's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1218.90/425.18
=2.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurobindo Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Aurobindo Pharma's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=128.364/153.0345*153.0345
=128.364

Current CPI (Mar. 2024) = 153.0345.

Aurobindo Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 49.892 94.103 81.137
201409 49.391 96.780 78.100
201412 54.204 96.780 85.710
201503 52.658 97.163 82.938
201506 56.489 99.841 86.586
201509 57.575 101.753 86.591
201512 59.961 102.901 89.174
201603 64.078 102.518 95.653
201606 64.326 105.961 92.903
201609 64.832 105.961 93.634
201612 66.702 105.196 97.035
201703 62.238 105.196 90.541
201706 62.789 107.109 89.712
201709 75.697 109.021 106.257
201712 74.041 109.404 103.569
201803 69.105 109.786 96.327
201806 72.570 111.317 99.767
201809 81.118 115.142 107.814
201812 88.287 115.142 117.342
201903 88.754 118.202 114.908
201906 91.411 120.880 115.727
201909 94.176 123.175 117.006
201912 98.980 126.235 119.993
202003 103.495 124.705 127.006
202006 99.258 127.000 119.605
202009 108.795 130.118 127.956
202012 108.419 130.889 126.763
202103 102.276 131.771 118.780
202106 97.135 134.084 110.863
202109 100.477 135.847 113.189
202112 102.212 138.161 113.216
202203 98.880 138.822 109.003
202206 105.372 142.347 113.283
202209 96.859 144.661 102.465
202212 108.967 145.763 114.403
202303 108.857 146.865 113.430
202306 115.884 150.280 118.008
202309 121.165 151.492 122.399
202312 124.567 152.924 124.657
202403 128.364 153.035 128.364

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aurobindo Pharma  (NSE:AUROPHARMA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Aurobindo Pharma Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurobindo Pharma (NSE:AUROPHARMA) Business Description

Traded in Other Exchanges
Address
Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032
Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (NSE:AUROPHARMA) Headlines

No Headlines